Iradimed (IRMD) Earns News Impact Score of 0.06

Media headlines about Iradimed (NASDAQ:IRMD) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Iradimed earned a media sentiment score of 0.06 on Accern’s scale. Accern also gave news articles about the medical equipment provider an impact score of 45.1351031098861 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Shares of Iradimed (IRMD) traded down $0.20 during trading hours on Friday, reaching $15.50. 32,256 shares of the company were exchanged, compared to its average volume of 21,322. The stock has a market cap of $163.61, a PE ratio of 119.23 and a beta of 1.61. Iradimed has a one year low of $7.85 and a one year high of $15.85.

Iradimed (NASDAQ:IRMD) last issued its earnings results on Monday, October 30th. The medical equipment provider reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.35. The company had revenue of $5.69 million for the quarter, compared to analysts’ expectations of $5.60 million. Iradimed had a net margin of 6.51% and a return on equity of 4.58%. The firm’s revenue was down 25.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.14 EPS. equities research analysts anticipate that Iradimed will post 0.05 EPS for the current fiscal year.

Several analysts have recently weighed in on the stock. ValuEngine upgraded shares of Iradimed from a “sell” rating to a “hold” rating in a research report on Friday, October 6th. Zacks Investment Research cut shares of Iradimed from a “buy” rating to a “hold” rating in a research report on Monday, October 2nd. Roth Capital assumed coverage on shares of Iradimed in a research report on Tuesday, October 31st. They set a “buy” rating and a $16.00 price objective on the stock. Finally, Credit Suisse Group assumed coverage on shares of Iradimed in a research report on Monday, November 27th. They set a “buy” rating and a $19.00 price objective on the stock. Two research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $15.33.

In related news, Director Monty K. Allen sold 1,898 shares of Iradimed stock in a transaction on Monday, December 4th. The shares were sold at an average price of $13.95, for a total value of $26,477.10. Following the transaction, the director now owns 9,062 shares in the company, valued at approximately $126,414.90. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 60.10% of the stock is owned by company insiders.

ILLEGAL ACTIVITY WARNING: This piece was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at

About Iradimed

IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.

Insider Buying and Selling by Quarter for Iradimed (NASDAQ:IRMD)

Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit